We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
The role of cardiac beta1- and beta2-adrenoceptor stimulation in heart failure.
Substantial evidence has accumulated that in the human heart both beta1- and beta2-adrenoceptors coexist. As a rule, the amount of beta2-adrenoceptors is higher in the atria (about 30% of the total beta-adrenoceptor population) than in the ventricular myocardium (about 20%). Both beta1- and beta2-adrenoceptors couple to adenylate cyclase and mediate positive inotropic effects of isoproterenol and epinephrine on isolated, electrically driven cardiac preparations. In the atria, stimulation of both beta1- and beta2-adrenoceptors causes maximal increases in contractile force; in the ventricular myocardium, however, only beta1-adrenoceptor stimulation maximally increases contractile force, whereas beta2-adrenoceptor stimulation evokes only submaximal increases. On the other hand, norepinephrine induces its positive inotropic effect on atrial and ventricular preparations solely via beta1-adrenoceptor stimulation. Because norepinephrine is the main transmitter of the human sympathetic nervous system, this indicates that under normal physiological conditions, the heart rate and contractility are under the control of cardiac beta1-adrenoceptors, whereas cardiac beta2-adrenoceptors play only a minor role, if at all. However, in situations of stress, when large amounts of epinephrine (acting at both beta1- and beta2-adrenoceptors with the same affinity) are released from the adrenal medulla, activation of cardiac beta2-adrenoceptors may contribute to an additional increase in heart rate and/or contractility. In chronic heart failure, cardiac beta-adrenoceptor function decreases (presumably due to endogenous "downregulation" by the elevated catecholamines), and this decrease is related to the severity of the disease (judged clinically by NYHA functional class). However, cardiac beta1- and beta2-adrenoceptors seem to be differentially affected in different kinds of heart failure: in end-stage dilated cardiomyopathy, beta1-adrenoceptors selectively decrease, whereas beta2-adrenoceptors are nearly normal. Under these (pathological) conditions, beta2-adrenoceptors may substitute for the loss in beta1-adrenoceptors, thereby maintaining contractility, at least partially. On the other hand, in end-stage ischemic cardiomyopathy, tetralogy of Fallot, and mitral valve disease, both beta1- and beta2-adrenoceptors concomitantly decrease. The reason for this differential regulation of cardiac beta1- and beta2-adrenoceptors in different forms of heart failure remains to be elucidated.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app